185 related articles for article (PubMed ID: 16261595)
1. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
Lauchle JO; Braun BS; Loh ML; Shannon K
Pediatr Blood Cancer; 2006 May; 46(5):579-85. PubMed ID: 16261595
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
3. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
4. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.
Side LE; Emanuel PD; Taylor B; Franklin J; Thompson P; Castleberry RP; Shannon KM
Blood; 1998 Jul; 92(1):267-72. PubMed ID: 9639526
[TBL] [Abstract][Full Text] [Related]
6. Juvenile myelomonocytic leukemia.
Emanuel PD
Curr Hematol Rep; 2004 May; 3(3):203-9. PubMed ID: 15087069
[TBL] [Abstract][Full Text] [Related]
7. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia.
Gitler AD; Kong Y; Choi JK; Zhu Y; Pear WS; Epstein JA
Pediatr Res; 2004 Apr; 55(4):581-4. PubMed ID: 14739366
[TBL] [Abstract][Full Text] [Related]
8. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM
Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
10. Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene.
Hingtgen CM; Roy SL; Clapp DW
Neuroscience; 2006; 137(2):637-45. PubMed ID: 16298082
[TBL] [Abstract][Full Text] [Related]
11. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
[TBL] [Abstract][Full Text] [Related]
12. Genetics of myeloid malignancies: pathogenetic and clinical implications.
Fröhling S; Scholl C; Gilliland DG; Levine RL
J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
[TBL] [Abstract][Full Text] [Related]
13. [P21ras--a central cross-road on intracellular signalling].
Levy O; Ramot Y; Rapoport M
Harefuah; 1997 Oct; 133(7-8):304-8. PubMed ID: 9418364
[No Abstract] [Full Text] [Related]
14. Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells.
Hiatt K; Ingram DA; Huddleston H; Spandau DF; Kapur R; Clapp DW
Am J Pathol; 2004 Apr; 164(4):1471-9. PubMed ID: 15039234
[TBL] [Abstract][Full Text] [Related]
15. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.
Kim A; Morgan K; Hasz DE; Wiesner SM; Lauchle JO; Geurts JL; Diers MD; Le DT; Kogan SC; Parada LF; Shannon K; Largaespada DA
Blood; 2007 Feb; 109(4):1687-91. PubMed ID: 17090653
[TBL] [Abstract][Full Text] [Related]
16. Nf1 and Gmcsf interact in myeloid leukemogenesis.
Birnbaum RA; O'Marcaigh A; Wardak Z; Zhang YY; Dranoff G; Jacks T; Clapp DW; Shannon KM
Mol Cell; 2000 Jan; 5(1):189-95. PubMed ID: 10678181
[TBL] [Abstract][Full Text] [Related]
17. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Emanuel PD
Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
[TBL] [Abstract][Full Text] [Related]
18. Mouse model for NRAS-induced leukemogenesis.
Parikh C; Ren R
Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
[TBL] [Abstract][Full Text] [Related]
19. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
20. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.
Liu YL; Yan Y; Webster C; Shao L; Lensing SY; Ni H; Feng W; Colorado N; Pathak R; Xiang Z; Hauer-Jensen M; Li S; Zhou D; Emanuel PD
Blood; 2016 Apr; 127(15):1912-22. PubMed ID: 26764354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]